" I am still expecting to see kidney function deteriorate in the placebo group and improve in the apabetalone/RVX-208 group."
Should RVX-208 improve eGRF, would this synergy be part and parcel of the existing RVX-208 patent, or would it need to be covered by a new patent?
Koo